- Report
- April 2023
- 116 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- August 2022
Global
From €1040EUR$1,090USD£872GBP
- Report
- February 2021
Global
From €2825EUR$2,960USD£2,367GBP
- Report
- February 2024
- 111 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2024
- 99 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2022
- 138 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- December 2022
- 45 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 117 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 88 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 94 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 55 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Glioma Drug market is a subset of the larger Brain Cancer Drug market. Glioma is a type of brain cancer that is caused by the abnormal growth of glial cells in the brain. Treatment for glioma typically involves surgery, radiation therapy, chemotherapy, and targeted therapy. Drugs used to treat glioma include temozolomide, bevacizumab, and lomustine.
Glioma drugs are typically used in combination with other treatments, such as radiation and surgery, to improve patient outcomes. The market for glioma drugs is expected to grow due to the increasing prevalence of brain cancer and the development of new treatments.
Some companies in the Glioma Drug market include Novartis, Merck, Roche, and Pfizer. Show Less Read more
